Background/Aims: Actinic keratosis area and severity index (AKASI) is a new assessment tool to quantify the severity of actinic damage on the head. Thus far, it has not been evaluated in monitoring the efficacy of field-directed topical treatments in actinic keratosis (AK) in routine clinical practice. Thus, the aim of this study was to determine treatment outcomes by using AKASI 3 months after the initiation of topical application of diclofenac sodium 3% in hyaluronic acid 2.5% gel (DFS) in patients with AKs on the head. Methods: We performed a retrospective analysis of patients with AKs who had AKASI scores prior to and after treatment with DFS. Results: Of the 24 patients included, 20 (83.3%) showed an improvement in AKASI, 2 (8.3%) a stable AKASI, and 2 (8.3%) a worsening of AKASI after a median (interquartile range) follow-up period of 91.5 days (89.8-104.3). The median AKASI reduction was 31.4% (16.7-59.1). The Wilcoxon test showed significant differences (p = 0.0008) between baseline and posttreatment AKASI values. Conclusions: AKASI is an easy-touse quantitative tool for assessing the treatment outcome of field-directed therapies. Field-directed therapies of AK should no longer be monitored by assessments based on lesion counts alone.
Introduction
Actinic keratosis (AK) is regarded as early in-situ squamous cell carcinoma (SCC) and shows an increasing prevalence among elderly people with fair skin types [1] . AKs are located on chronically UV-damaged areas. They are considered as chronic disease. The risk of a single AK lesion progressing into invasive SCC ranges from 0.025 to 16% per year [2] . Single AK lesions present as erythematous macules, keratotic papules, or plaques, and can be clinically diagnosed [3] . Beside these detectable lesions, the adjacent skin often presents further subclinical, nonvisible lesions. Thus, the entire area of sun-exposed skin is affected by both clinical and subclinical AKs resulting in field cancerization. Since it is not possible to predict when and which AK lesions will transform into invasive SCC, treatment of the whole sun-damaged field is advised [4] .
Nevertheless, AKs are commonly classified based on the overall thickness of individual lesions [5] . Recent studies show that the thickness of AK does not predict its degree of dysplasia or correlate with established histological grading systems [6, 7] . Furthermore, a lesion-based classification scheme does not adequately represent the whole area affected by AK. To overcome this lack of reproducible assessment of field cancerization, the actinic keratosis area and severity index (AKASI) has recently been published [8] . This assessment tool provides an objective evaluation of field cancerization (AK severity) on the head. Thus, the head is divided into 4 regions and is evaluated according to its affected area based on typical parameters such as erythema, thickness, and distribution.
AKASI offers objective monitoring and the comparison of treatment outcomes. It provides values which are independent of variable grading factors such as the size of the treated field and the number and characteristics of various AK lesions. Until now, AKASI has not been used to monitor treatment outcomes in routine clinical practice [8] .
Hence, the aim of this study was to evaluate the treatment outcome of diclofenac 3% in hyaluronic acid 2.5% (DFS) in patients with AKs on the head. DFS is a topical nonsteroidal anti-inflammatory agent. Diclofenac inhibits cyclo-oxygenase-2 (COX-2) activity and COX-2-mediated prostaglandin E2, which have been shown to be involved in tumour angiogenesis and in tumour cell proliferation [9, 10] . It has been reported to be well tolerated and effective [11] . Thus, DFS is a well-established fielddirected treatment modality of AKs and is frequently used in clinical practice [12] . This is the first study to implement AKASI to determine treatment efficacy.
Materials and Methods

Study Population
This retrospective study was approved by the ethics review board of Ruhr University (Bochum, Germany; No. 17-5984-BR) and conducted according to the Declaration of Helsinki. The database at the Skin Cancer Centre of Ruhr University was searched for patients with AK on the head who received topical treatment with DFS and those who had a documented AKASI as well as a physician global assessment (PGA) score prior to (V0) and after treatment (V1). In our clinical practice the usual follow-up period for AK patients is about 3 months and patients are asked at every visit if they had used the treatment adequately. Only patients who confirmed the use of DFS twice daily for the 12-week treatment period on affected skin of the head were eligible for evaluation. Patients on immunosuppressive therapy were excluded from this study. To avoid inter-rater differences, only patients who had been rated by the same physician at both visits (V0 and V1) were included in the analysis.
Data Assessment
Prior to any therapy of AKs on the head, patients are routinely monitored by AKASI and PGA scoring in our outpatient clinic. In the group of eligible patients, these scores were performed by 4 investigators (M.H.S., R.K., J.S., L.S.). Assessment of AKASI has been described in detail previously [8] . Total AKASI of the head can range from 0 to 18 by adding the 4 subscores of the scalp, face, as well as right/left cheek, nose and chin. For PGA scoring, the following categories were used: "none" (0), "light" (1), "moderate" (2), "severe" (3) and "very severe" (4).
Statistical Analysis
Data analysis was performed using the statistical software package MedCalc, version 17.4.4 (Ostend, Belgium). The distribution 
Results
A total of 24 patients with a median (IQR) age of 75 (69-81) years were included in this study. The majority of patients were male (83.3%) and presented with Fitzpatrick skin type II (79.2%), and 50% of the study population had a history of being treated with at least 1 or more topical treatments for their AKs. The median time period from baseline (prior to treatment) and follow-up visit was 91.5 days (89.8-104.3). Further demographic and clinical characteristics are shown in Table 1 .
Overall, 20 (83.3%) patients showed a decrease in AKASI at the follow-up visit compared to the baseline visit, 2 (8.3%) patients had unchanged AKASI values at both visits, and 2 (8.3%) patients showed increased AKA-SI values. The median reduction was 31.4% (16.7-59.1). Box-and-whisker plot demonstrating differences in AKASI prior to and after treatment. The Wilcoxon test showed significant differences between AKASI at the baseline visit (V0) and at the follow-up visit (V1) for the standard AKASI (V1a; p = 0.0008) and the modified AKASI (only treated areas were assessed; V1b; p = 0.0001). The orange circle is an outlier, larger than the upper quartile plus 1.5 times the IQR.
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Diclofenac Sodium 3% Gel Diminishes AKASI The Wilcoxon test showed significant differences (p = 0.0008) between V0 and V1 AKASI values (Fig. 2a) . Subgroup analysis of the 20 patients with an AKASI reduction showed a median value of 42.9% (25.1-62.5). Subgroup analysis of treatment-naïve patients (50.0%) and patients with a positive history of at least 1 or more topical treatments used (50.0%) showed a median AKASI reduction of 37.3% (21.2-61.0) and 29.4% (12.5-59.1), respectively (Fig. 3) . The Mann-Whitney U test showed no significant differences between AKASI changes in these 2 groups (p = 0. 6650). The Spearman rank coefficient correlation between AKASI and PGA indicated that these measures of AK severity were strongly correlated at baseline visit (p < 0.0001; r = 0.79; 95% CI 0.57-0.91) and less at the follow-up visit (p = 0.0010; r = 0.63; 95% CI 0.30-0.82). The analysis of treatment-adapted AKASI (only areas which received treatment were assessed) showed a median reduction of 42.9% (19.2-59.1). The Wilcoxon test showed highly significant differences (p = 0.0001) between V0 and V1 AKASI values (Fig. 2b) .
Discussion
This is the first clinical study to use AKASI in measuring treatment outcomes in patients with AK on the head who have been treated with DFS. Significant differences in AKASI before and after treatment with DFS could be demonstrated. AKASI was an easy-to-use assessment tool to monitor AK severity in clinical practice. Taking into consideration that AKs represent chronic disease, AKASI may be useful in longitudinal studies or in occupational issues to document disease progression. AKASI allows the clinician to categorize different severity levels of AK and may help in assigning treatment options accordingly. Treatment outcomes can easily be measured and com- pared objectively. However, more data on AKASI and its correlation with the risk of progression of AKs into invasive SCC are required. This may affect the choice of treatment and the urgency of its implementation.
This study showed a significant reduction in AKASI before and after treatment with DFS with a median follow-up period of 91.5 days. The median reduction was 31.4% based on the analysis of all 4 regions on the head (standard AKASI), irrespective of the fact that some areas may not have been affected by AKs and so may not have required treatment. On the one hand, it is advantageous to assess a global score of disease severity and take all AK lesions and all areas of the head into account. However, in certain scenarios such as AKs developing on previously clear and non-treated skin, the risk is that this global score may inadvertently appear worse, i.e., the treatment appears to have worsened the disease when in fact the treated areas have improved. Therefore, we analysed a "modified" AKASI based solely on treated areas. This subgroup analysis showed a median value of 42.9% with 4 patients showing an AKASI improvement of 100% compared to 2 patients in the overall AKASI group. As the AKASI is an objective assessment tool for the overall disease severity on the head, a standard AKASI (including the entire head) is recommended, but one should be aware that in certain scenarios described above the results should be interpreted with caution.
Besides disease monitoring, AKASI is a reproducible, standardized, and comparable assessment tool in clinical trials [8] . Commonly, the primary endpoint in new AK treatment evaluation is complete clearance rates [13] . Thus, it is based on counting individual AK lesions before and after treatment, which is unreliable and not reproducible. The lesion count may also be affected by alterations in the appearance of subclinical lesions during treatment [14] . This effect may influence a lesion count as opposed to a field-directed evaluation approach such as AKASI [8] .
Moreover, AKASI also takes hyperkeratotic lesions (grade III) into account [5] . In the past, most AK studies excluded hyperkeratotic lesions assuming a higher risk of progression into invasive carcinoma. However, a recent study has shown that it is not possible to draw a correlation from clinical appearance to histology [7] . Furthermore, another study revealed that the thickness of AKs does not predict its dysplastic severity and thus its aggressiveness [6] . Therefore, an assessment tool taking the whole field as well as hyperkeratotic lesions into account was required. As recurrence often appears within a treated field, a field-directed evaluation score should assess both clinical outcomes directly after treatment and longterm follow-up.
This study showed a median AKASI at baseline of 3.0 resembling a "light" AKASI score which is similar to the pivotal study (AKASI 2.88 = light). The median PGA of 1.0 at baseline visit correlates with this AKASI [8] . The Spearman rank coefficient is well correlated with these 2 scores at baseline and following treatment. A therapeutic decision to use DFS treatment seems to be more likely in patients with mild AKASI than in patients with a severe or very severe disease. Hence, DFS is mainly used in an ambulatory or outpatient setting where most patients have mild to moderate disease. Additionally, we investigated the differences between treatment-naïve patients and those who had at least 1 or more AK treatments on the head, but we did not find significant differences between these 2 groups.
Moreover, the results of our study are comparable with randomized control trials, which have investigated the complete resolution of lesions. Three different studies show a complete resolution of 29% [15] , 31% [16] , and 47% [17] , respectively. When AKASI was calculated for treated areas only, we found a median AKASI reduction of 42.9%, which might be equivalent. Lesion counting can be time consuming and it is particularly challenging in patients with severe photodamage in which contiguous AKs may coalesce into large areas of inflamed and sundamaged skin [8] .
The limitations of our study were the small number of patients included and the retrospective design. We were also unable to confirm patients' compliance to therapy. However, all patients were asked, at every visit, if they had used the treatment adequately and advised to continue using the product. Moreover, it would be of great interest to evaluate the overall outcome in patients more severely affected by AK (higher AKASI values), but in those with mild disease the real-life scenario of using DFS was demonstrated by the low AKASI at baseline.
In conclusion, AKASI is a quick, easy-to-use field-directed assessment tool which has been proven to be reliable in monitoring treatment with DFS in clinical practice. Further data on different AK treatment modalities are needed to compare and evaluate these results. In future, field-directed therapies of AK should no longer be monitored by single-directed assessments like lesion counts.
